

Dieter Steinhilber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1871358/publications.pdf>

Version: 2024-02-01

82
papers

2,585
citations

218677

26
h-index

223800

46
g-index

82
all docs

82
docs citations

82
times ranked

4189
citing authors

#	ARTICLE	IF	CITATIONS
1	5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 331-339.	2.4	371
2	Vitamin D in inflammatory diseases. <i>Frontiers in Physiology</i> , 2014, 5, 244.	2.8	192
3	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. <i>Oncotarget</i> , 2016, 7, 32462-32477.	1.8	130
4	Recent Advances in the Search for Novel 5- ω -Lipoxygenase Inhibitors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 114, 70-77.	2.5	110
5	Vitamin D Promotes Vascular Regeneration. <i>Circulation</i> , 2014, 130, 976-986.	1.6	91
6	Lipoxin and resolvin biosynthesis is dependent on 5- ω -lipoxygenase activating protein. <i>FASEB Journal</i> , 2015, 29, 5029-5043.	0.5	70
7	Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators—What is the Evidence so far?. <i>Frontiers in Pharmacology</i> , 2022, 13, 838782.	3.5	70
8	A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7703-7724.	6.4	69
9	5-Lipoxygenase: Underappreciated Role of a Pro-Inflammatory Enzyme in Tumorigenesis. <i>Frontiers in Pharmacology</i> , 2010, 1, 143.	3.5	52
10	5-Lipoxygenase Is a Direct Target of miR-19a-3p and miR-125b-5p. <i>Journal of Immunology</i> , 2015, 194, 1646-1653.	0.8	51
11	S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. <i>Journal of Clinical Investigation</i> , 2020, 130, 5461-5476.	8.2	48
12	5-Lipoxygenase Is a Candidate Target for Therapeutic Management of Stem Cell–like Cells in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2014, 74, 5244-5255.	0.9	47
13	Small molecules with anti-inflammatory properties in clinical development. , 2016, 157, 163-187.		45
14	<i>N</i> -Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor β Modulators. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 61-81.	6.4	44
15	Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 155-158.	2.8	43
16	Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade. <i>Biochemical Pharmacology</i> , 2018, 158, 161-173.	4.4	41
17	Roles of coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP) in cellular leukotriene biosynthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11371-11376.	7.1	40
18	NSAIDs Ibuprofen, Indometacin and Diclofenac do not interact with Farnesoid X Receptor. <i>Scientific Reports</i> , 2015, 5, 14782.	3.3	39

#	ARTICLE	IF	CITATIONS
19	Iron-Dependent Trafficking of 5-Lipoxygenase and Impact on Human Macrophage Activation. <i>Frontiers in Immunology</i> , 2019, 10, 1347.	4.8	39
20	Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?. , 2016, 157, 43-64.		36
21	Apoptotic Cancer Cells Suppress 5-Lipoxygenase in Tumor-Associated Macrophages. <i>Journal of Immunology</i> , 2018, 200, 857-868.	0.8	34
22	Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1169-1172.	2.8	33
23	Epigenetic Regulation of Angiogenesis by JARID1B-Induced Repression of HOXA5. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1645-1652.	2.4	33
24	Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5758-5764.	6.4	31
25	miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. <i>FASEB Journal</i> , 2019, 33, 6933-6947.	0.5	30
26	Sphingosine-1-phosphate (S1P) induces potent anti-inflammatory effects <i>in vitro</i> and <i>in vivo</i> by S1P receptor 4-mediated suppression of 5-lipoxygenase activity. <i>FASEB Journal</i> , 2019, 33, 1711-1726.	0.5	30
27	Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 302-311.	5.5	29
28	Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. <i>Biochemical Society Transactions</i> , 2015, 43, 707-714.	3.4	29
29	Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action. <i>Toxicology and Applied Pharmacology</i> , 2015, 287, 67-76.	2.8	27
30	The Histone Demethylase PHF8 Is Essential for Endothelial Cell Migration. <i>PLoS ONE</i> , 2016, 11, e0146645.	2.5	27
31	Beyond leukotriene formation – The noncanonical functions of 5-lipoxygenase. <i>Prostaglandins and Other Lipid Mediators</i> , 2019, 142, 24-32.	1.9	26
32	The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 1297.	3.5	26
33	Thyroxine and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPAR β . <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6727-6740.	6.4	26
34	UPF1 regulates myeloid cell functions and S100A9 expression by the hnRNP E2/miRNA-328 balance. <i>Scientific Reports</i> , 2016, 6, 31995.	3.3	25
35	Characterization of the interaction of human 5-lipoxygenase with its activating protein FLAP. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 1465-1472.	2.4	23
36	How to effectively treat acute leukemia patients bearing MLL-rearrangements ?. <i>Biochemical Pharmacology</i> , 2018, 147, 183-190.	4.4	23

#	ARTICLE	IF	CITATIONS
37	PAFAH1B1 and the lncRNA <i>NONHSAT073641</i> maintain an angiogenic phenotype in human endothelial cells. <i>Acta Physiologica</i> , 2016, 218, 13-27.	3.8	22
38	Cellular analysis of the histamine H4 receptor in human myeloid cells. <i>Biochemical Pharmacology</i> , 2016, 103, 74-84.	4.4	21
39	Development of novel aminothiazole-comprising 5-LO inhibitors. <i>Future Medicinal Chemistry</i> , 2016, 8, 149-164.	2.3	21
40	5-Lipoxygenase is a direct p53 target gene in humans. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 1003-1016.	1.9	20
41	Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8443-8460.	6.4	19
42	Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE. <i>Biochemical Pharmacology</i> , 2017, 146, 53-62.	4.4	18
43	Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418. <i>Biochemical Pharmacology</i> , 2017, 125, 55-74.	4.4	18
44	Anti-inflammatory nitro-fatty acids suppress tumor growth by triggering mitochondrial dysfunction and activation of the intrinsic apoptotic pathway in colorectal cancer cells. <i>Biochemical Pharmacology</i> , 2018, 155, 48-60.	4.4	18
45	Zafirlukast Is a Dual Modulator of Human Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptor β . <i>Frontiers in Pharmacology</i> , 2019, 10, 263.	3.5	18
46	Carborane-Based Analogues of 5-Lipoxygenase Inhibitors Co-Inhibit Heat Shock Protein 90 in HCT116 Cells. <i>ChemMedChem</i> , 2019, 14, 255-261.	3.2	18
47	Chiral chromatography-tandem mass spectrometry applied to the determination of pro-resolving lipid mediators. <i>Journal of Chromatography A</i> , 2014, 1360, 150-163.	3.7	16
48	Heterodimer formation with retinoic acid receptor RXR α modulates coactivator recruitment by peroxisome proliferator-activated receptor PPAR β . <i>Journal of Biological Chemistry</i> , 2021, 297, 100814.	3.4	16
49	Carborane-901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway. <i>ChemMedChem</i> , 2017, 12, 1081-1086.	3.2	15
50	Regulation of Eicosanoid Pathways by MicroRNAs. <i>Frontiers in Pharmacology</i> , 2019, 10, 824.	3.5	15
51	Analysis of proximal <i>ALOX5</i> promoter binding proteins by quantitative proteomics. <i>FEBS Journal</i> , 2020, 287, 4481-4499.	4.7	14
52	Melleolides from Honey Mushroom Inhibit 5-Lipoxygenase via Cys159. <i>Cell Chemical Biology</i> , 2019, 26, 60-70.e4.	5.2	13
53	4-(4-Chlorophenyl)thiazol-2-amines as pioneers of potential neurodegenerative therapeutics with anti-inflammatory properties based on dual DNase I and 5-LO inhibition. <i>Bioorganic Chemistry</i> , 2020, 95, 103528.	4.1	13
54	Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications. <i>Drug Discovery Today</i> , 2020, 25, 1744-1753.	6.4	13

#	ARTICLE	IF	CITATIONS
55	Novel Pirinixic Acids as PPAR α Preferential Dual PPAR α/β Agonists. QSAR and Combinatorial Science, 2009, 28, 576-586.	1.4	12
56	Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy. European Journal of Medicinal Chemistry, 2015, 89, 503-523.	5.5	12
57	Thermodynamic properties of leukotriene A 4 hydrolase inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 5243-5248.	3.0	12
58	Stabilisation and characterisation of the isolated regulatory domain of human 5-lipoxygenase. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1538-1547.	2.4	11
59	Mass Spectrometry-Based Proteomics Approach Characterizes the Dual Functionality of miR-328 in Monocytes. Frontiers in Pharmacology, 2019, 10, 640.	3.5	11
60	AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3. Oncotarget, 2015, 6, 25784-25800.	1.8	11
61	Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA ₄ Hydrolase. ACS Medicinal Chemistry Letters, 2020, 11, 298-302.	2.8	10
62	Dicer up-regulation by inhibition of specific proteolysis in differentiating monocytic cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8573-8583.	7.1	10
63	Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor β Agonists/Soluble Epoxide Hydrolase Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 17259-17276.	6.4	10
64	Characterization of the molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles. Biochemical Pharmacology, 2017, 123, 52-62.	4.4	9
65	Pirinixic acids: flexible fatty acid mimetics with various biological activities. Future Medicinal Chemistry, 2015, 7, 1597-1616.	2.3	8
66	Systematic Assessment of Fragment Identification for Multitarget Drug Design. ChemMedChem, 2021, 16, 1088-1092.	3.2	8
67	Modulation of microRNA processing by 5-lipoxygenase. FASEB Journal, 2021, 35, e21193.	0.5	8
68	Borcalein: a Carborane-Based Analogue of Baicalein with 12-lipoxygenase-Independent Toxicity. ChemMedChem, 2022, 17, .	3.2	8
69	Inhibitors of Human 5-Lipoxygenase Potently Interfere With Prostaglandin Transport. Frontiers in Pharmacology, 2021, 12, 782584.	3.5	7
70	TGF β /SMAD signalling modulates MLL and MLL-AF4 mediated 5-lipoxygenase promoter activation. Prostaglandins and Other Lipid Mediators, 2017, 133, 60-67.	1.9	6
71	Elucidation of chemical modifier reactivity towards peptides and proteins and the analysis of specific fragmentation by matrix-assisted laser desorption/ionization collision-induced dissociation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2019, 33, 40-49.	1.5	6
72	Development and in-vitro Profiling of Dual FXR/LTA4H Modulators. ChemMedChem, 2021, 16, 2366-2374.	3.2	6

#	ARTICLE	IF	CITATIONS
73	Identification and Characterization of a New Protein Isoform of Human 5-Lipoxygenase. PLoS ONE, 2016, 11, e0166591.	2.5	6
74	Epigenetic control of microsomal prostaglandin E synthase-1 by HDAC-mediated recruitment of p300. Journal of Lipid Research, 2017, 58, 386-392.	4.2	5
75	Structural Modifications Yield Novel Insights Into the Intriguing Pharmacodynamic Potential of Anti-inflammatory Nitro-Fatty Acids. Frontiers in Pharmacology, 2021, 12, 715076.	3.5	5
76	Characterization and cellular localization of human 5-lipoxygenase and its protein isoforms 5-LO ¹ , 5-LO ² and 5-LO ³ . Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 561-571.	2.4	4
77	Structure optimization of a new class of PPAR ³ antagonists. Bioorganic and Medicinal Chemistry, 2019, 27, 115082.	3.0	4
78	Repurposing of 8-Hydroxyquinoline-Based Butyrylcholinesterase and Cathepsin B Ligands as Potent Nonpeptidic Deoxyribonuclease I Inhibitors. ChemMedChem, 2022, 17, .	3.2	4
79	Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy. Antioxidants and Redox Signaling, 2018, 28, 1265-1285.	5.4	3
80	Targeting the 5-Lipoxygenase as a Novel Principle of Stem Cell Therapy In Acute Myeloid Leukemia. Blood, 2010, 116, 1846-1846.	1.4	1
81	Response to Letter Regarding Article, "Vitamin D Promotes Vascular Regeneration". Circulation, 2015, 131, e515-6.	1.6	0
82	Enzymatically Inactive 5-Lipoxygenase Inhibits Wnt-Signaling Activation Induced by Leukemia Inducing Oncogenes.. Blood, 2012, 120, 2424-2424.	1.4	0